The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Measured by its binding activity in a functional ELISA against immobilized FMC63 mAb (0.2 μg/well). The linear range is 0.04 - 0.6 μg/mL.
< 1.000 Eu/µg
>95% by SDS-PAGE .
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Store at 4°C prior to reconstitution. Store at -80°C. Avoid freeze / thaw cycle.
pH: 7.40 Constituents: 95% PBS, 5% Trehalose
This product is an active protein and may elicit a biological response in vivo, handle with caution.
It is recommended to reconstitute the lyophilized protein in sterile deionized water to a final concentration of 200 ug/ml. Solubilize for 30 to 60 minutes at room temperature with occasional gentle mixing. Carrier protein (0.1% HSA or BSA) is strongly recommended for further dilution and long term storage.
Antibody deficiency due to defect in CD19, included
B lymphocyte antigen CD19
B lymphocyte surface antigen B4
B-lymphocyte antigen CD19
B-lymphocyte surface antigen B4
Differentiation antigen CD19
T-cell surface antigen Leu-12
Assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation.
Involvement in disease
Defects in CD19 are the cause of immunodeficiency common variable type 3 (CVID3) [MIM:613493]; also called antibody deficiency due to CD19 defect. CVID3 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B cells is usually in the normal range, but can be low.